Evidence Table E2. CONTINUOUS outcomes for class RETINOID (TOPICAL).

Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

E.01.01 Adapalene (0.03%) Adapalene (0.1%)

338 Inflammatory change (%)

Count location: Face. 

Short (4) Percent change: -8 Percent change: -25

Parallel Mild/mod/sev

È N=72

78 Total lesions change (%)

Count location: Face excluding nose. 

N=89 Short (4) Percent change: -30 Percent change: -45

338 Inflammatory change (%)

Count location: Face. 

N=72 Mid (12) Percent change: -45 Percent change: -65 NS 0.05

Non-inflammatory (count) Mid (12) Raw count: 28 (22.5) Raw count: 20 (26.9) NS 0.05

Severity (leeds) Mid (12) Measure: 1 (0.49) Measure: 0 (0.25) 0.05

78 Total lesions change (%)

Count location: Face excluding nose. 

N=89 Mid (12) Percent change: -53 Percent change: -72

E.01.01 Adapalene-delayed Adapalene-immediate

92 Dryness (score) Short (2) Measure: 1 Measure: 1

Parallel split face 

Mild/mod

Í N=25 NS

Erythema (score) Short (2) Measure: 1 Measure: 1 NS

E.01.02 Adapalene Tretinoin

93 Desquamation Short (0) Measure: 0 (0.24) Measure: 0 (0.2)

Parallel split face 

Mild/mod

È N=100 1

Dryness (score) Short (0) Measure: 0 (0.3) Measure: 0 (0.31) 1

Erythema (score) Short (0) Measure: 1 (0.52) Measure: 1 (0.52) NS

Stinging/burning Short (0) Measure: 0 (0.) Measure: 0 (0.) 1

Total adverse skin symptom (score) Short (0) Measure: 1 (0.7) Measure: 1 (0.68) NS

Desquamation Short (4) Measure: 0 (0.71) Measure: 1 (0.87) 0.034

Erythema (score) Short (4) Measure: 2 (0.87) Measure: 2 (0.52) 0.021

100 Inflammatory (count)

Count location: Entire face. Baseline counts: 

26 (Target) / 26 (Comparator)

Short (4) Percent Change*: -23 Percent Change*: -19

Parallel Mod

N=297 NS

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 1 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

80 Inflammatory change (%)

Count location: Face excluding nose. 

Short (4) Percent change: -39 Percent change: -35

Parallel 

È N=268

140 Inflammatory change (%) Short (4) Percent change: -45 Percent change: -35

Parallel Mild/mod

È N=105 NS

93 Local reactions/Dryness (score) Short (4) Measure: 1 (0.78) Measure: 1 (0.89)

Parallel split face 

Mild/mod

N=100 0.017

100 Non-inflammatory (count)

Count location: Entire face. Baseline counts: 

50 (Target) / 52 (Comparator)

Short (4) Percent Change*: -28 Percent Change*: -25

Parallel Mod

N=297 NS

80 Non-inflammatory change (%)

Count location: Face excluding nose. 

Short (4) Percent change: -30 Percent change: -16

Parallel 

È N=268

140 Non-inflammatory change (%) Short (4) Percent change: -41 Percent change: -42

Parallel Mild/mod

È N=105 NS

Severity (leeds) [per protocol] Short (4) Measure: 1 (0.7) Measure: 1 (0.7) NS

Severity change (leeds %) [per protocol] Short (4) Measure: -42 (36.4) Measure: -34 (36.7) NS

93 Stinging/burning Short (4) Measure: 0 (0.82) Measure: 1 (0.85)

Parallel split face 

Mild/mod

N=100 NS

Total adverse skin symptoms (score) Short (4) Measure: 4 (2.33) Measure: 5 (2.64) 0.011

306 % Burning grade I Mid (12) Measure: 3 Measure: 8

Parallel Mod

È N=288 NS

% Dryness grade I Mid (12) Measure: 36 Measure: 48 0.05

% Erythema grade I Mid (12) Measure: 35 Measure: 45 0.05

% Scaling grade Mid (12) Measure: 22 Measure: 42 0.05

100 Inflammatory (count)

Count location: Entire face. Baseline counts: 

26 (Target) / 26 (Comparator)

È N=297 Mid (12) Percent Change*: -42 Percent Change*: -46 NS

Inflammatory change (%)

Count location: Entire face. 

Mid (12) Percent change: -47 Percent change: -50 NS

140 Inflammatory change (%) Mid (12) Percent change: -58 Percent change: -61

Parallel Mild/mod

N=105 NS

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 2 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

80 Inflammatory change (%)

Count location: Face excluding nose. 

Mid (12) Percent change: -65 Percent change: -65

Parallel 

È N=268

306 Inflammatory change (%) Mid (12) Percent change: -48 Percent change: -38

Parallel Mod

N=288 0.01

100 Non-inflammatory (count)

Count location: Entire face. Baseline counts: 

50 (Target) / 52 (Comparator)

È N=297 Mid (12) Percent Change*: -56 Percent Change*: -52 NS

306 È N=288 Non-inflammatory change (%) Mid (12) Percent change: -46 Percent change: -33 0.05

80 Non-inflammatory change (%)

Count location: Face excluding nose. 

Mid (12) Percent change: -55 Percent change: -60

Parallel 

N=268

100 Non-inflammatory change (%)

Count location: Entire face. 

Mid (12) Percent change: -57 Percent change: -54

Parallel Mod

È N=297 NS

140 Non-inflammatory change (%) Mid (12) Percent change: -50 Percent change: -61

Parallel Mild/mod

N=105 NS

100 Severity (leeds)

Count location: Entire face. 

Mid (12) Measure: 1 .001 Measure: 1

Parallel Mod

N=297 .001 NS

140 Severity (leeds) [intention to treat] Mid (12) Measure: 1 (0.6) Measure: 1 (0.6)

Parallel Mild/mod

N=105 NS

Severity (leeds) [per protocol] Mid (12) Measure: 1 (0.6) Measure: 1 (0.4) NS

Severity change (leeds %) [intention to 

treat]

Mid (12) Measure: -51 (36.6) Measure: -62 (31.3) NS

Severity change (leeds %) [per protocol] Mid (12) Measure: -56 (36.1) Measure: -72 (21.2) NS

100 Total lesions change (%)

Count location: Entire face. 

Mid (12) Percent change: -54 Percent change: -52

Parallel Mod

N=297 NS

306 È N=288 Total lesions change (%) Mid (12) Percent change: -49 Percent change: -37 0.01

E.01.02 Adapalene (0.03%) Tretinoin

338 Inflammatory change (%)

Count location: Face. 

Short (4) Percent change: -8 Percent change: 3

Parallel Mild/mod/sev

È N=72

78 Total lesions change (%)

Count location: Face excluding nose. 

N=89 Short (4) Percent change: -30 Percent change: -50

338 Inflammatory change (%)

Count location: Face. 

N=72 Mid (12) Percent change: -45 Percent change: -42 0.05

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 3 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

338 Non-inflammatory (count)

Count location: Face. 

Mid (12) Raw count: 28 (22.5) Raw count: 17 (10.8)

Parallel Mild/mod/sev

È N=72 NS 0.05

Severity (leeds) Mid (12) Measure: 1 (0.49) Measure: 1 (0.83) 0.05

78 Total lesions change (%)

Count location: Face excluding nose. 

N=89 Mid (12) Percent change: -53 Percent change: -78

E.01.02 Adapalene (0.1%) Tretinoin

338 Inflammatory change (%)

Count location: Face. 

Short (4) Percent change: -25 Percent change: 3

Parallel Mild/mod/sev

È N=72

78 Total lesions change (%)

Count location: Face excluding nose. 

N=89 Short (4) Percent change: -45 Percent change: -50

Inflammatory (count)

Baseline counts: 35 (Target) / 41 

(Comparator)

Mid (12) Percent Change*: -69 Percent Change*: -73

338 Inflammatory change (%)

Count location: Face. 

N=72 Mid (12) Percent change: -65 NS Percent change: -42 0.05

Non-inflammatory (count) Mid (12) Raw count: 20 (26.9) NS Raw count: 17 (10.8) NS NS*

78 Non-inflammatory (count)

Count location: Face excluding nose. Baseline 

counts: 60 (Target) / 88 (Comparator)

N=89 Mid (12) Percent Change*: -77 Percent Change*: -81

338 Severity (leeds)

Count location: Face. 

N=72 Mid (12) Measure: 0 (0.25) Measure: 1 (0.83) NS

78 Severity (leeds)

Count location: Face excluding nose. 

N=89 Mid (12) Measure: 0 Measure: 1 0.01

Total lesions change (%) Mid (12) Percent change: -72 Percent change: -78

E.02.01 Isotretinoin Vehicle

173 Inflammatory (count)

Count location: Face. Baseline counts: 40 

(Target) / 44 (Comparator)

Short (4) Percent Change*: -05 NS Percent Change*: -05

Parallel Mild/mod

NS "signific

ant"

È N=77

Non-inflammatory (count)

Count location: Face. Baseline counts: 45 

(Target) / 49 (Comparator)

Short (4) Percent Change*: -16 .05 Percent Change*: 02

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 4 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

173 Severity (leeds)

Count location: Face. 

Short (4) Measure: 1 NS Measure: 1

Parallel Mild/mod

È N=77 NS NS

54 Inflammatory change (%)

Between P-value: no P value given.

Short (5) Percent change: -25 Percent change: -15

Parallel 

"signific

ant"

N=313

Non-inflammatory change (%) Short (5) Percent change: -26 Percent change: -17 NS

Severity change (cook %) Short (5) Measure: -18 Measure: -11 NS

Inflammatory change (%)

Between P-value: no P value given.

Mid (11) Percent change: -50 Percent change: -23 "signific

ant"

Non-inflammatory change (%) Mid (11) Percent change: -36 Percent change: -13 "signific

ant"

Severity change (cook %) Mid (11) Measure: -33 Measure: -18 "signific

ant"

173 Inflammatory (count)

Count location: Face. Baseline counts: 40 

(Target) / 44 (Comparator)

Mid (12) Percent Change*: -33 .01 Percent Change*: 09

Parallel Mild/mod

N=77 NS 0.01

Non-inflammatory (count)

Count location: Face. Baseline counts: 45 

(Target) / 49 (Comparator)

Mid (12) Percent Change*: -47 .01 Percent Change*: 06 NS 0.01

Severity (leeds)

Count location: Face. 

Mid (12) Measure: 0 .01 Measure: 1 0.05

54 Inflammatory change (%)

Between P-value: no P value given.

Long (14 Percent change: -55 Percent change: -25

Parallel 

"signific

ant"

N=313

Non-inflammatory change (%) Long (14 Percent change: -46 Percent change: -14 "signific

ant"

Severity change (cook %) Long (14 Measure: -40 Measure: -20 "signific

ant"

E.02.01 Isotretinoin (0.05%) Vehicle

202 Closed comedones (count)

Count location: Face. Baseline counts: 23 

(Target) / 18 (Comparator)

Short (4) Percent Change*: -19 NS Percent Change*: 11

Parallel Mild/mod

N=82 NS NS*

Papules (count)

Count location: Face. Baseline counts: 23 

(Target) / 20 (Comparator)

Short (4) Percent Change*: -26 .01 Percent Change*: -30 .01 NS*

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 5 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

202 Closed comedones (count)

Count location: Face. Baseline counts: 23 

(Target) / 18 (Comparator)

Mid (12) Percent Change*: -47 .01 Percent Change*: -14

Parallel Mild/mod

N=82 NS NS*

Papules (count)

Count location: Face. Baseline counts: 23 

(Target) / 20 (Comparator)

Mid (12) Percent Change*: -34 .001 Percent Change*: -49 .01 NS*

E.02.01 Isotretinoin (0.1%) Vehicle

202 Closed comedones (count)

Count location: Face. Baseline counts: 21 

(Target) / 18 (Comparator)

Short (4) Percent Change*: -20 NS Percent Change*: 11

Parallel Mild/mod

N=82 NS NS*

Papules (count)

Count location: Face. Baseline counts: 23 

(Target) / 20 (Comparator)

Short (4) Percent Change*: -32 .01 Percent Change*: -30 .01 NS*

Closed comedones (count)

Count location: Face. Baseline counts: 21 

(Target) / 18 (Comparator)

Mid (12) Percent Change*: -46 .01 Percent Change*: -14 NS NS*

Papules (count)

Count location: Face. Baseline counts: 23 

(Target) / 20 (Comparator)

Mid (12) Percent Change*: -60 .01 Percent Change*: -49 .01 NS*

E.02.02 Isotretinoin Benzoyl peroxide

173 Inflammatory (count)

Count location: Face. Baseline counts: 40 

(Target) / 44 (Comparator)

Short (4) Percent Change*: -05 NS Percent Change*: -43

Parallel Mild/mod

"signific

ant"

È N=77

Non-inflammatory (count)

Count location: Face. Baseline counts: 45 

(Target) / 48 (Comparator)

Short (4) Percent Change*: -16 .05 Percent Change*: -23 .05

Severity (leeds)

Count location: Face. 

Short (4) Measure: 1 NS Measure: 1 .01 NS

Inflammatory (count)

Count location: Face. Baseline counts: 40 

(Target) / 44 (Comparator)

Mid (12) Percent Change*: -33 .01 Percent Change*: -52 .01 0.01

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 6 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

173 Non-inflammatory (count)

Count location: Face. Baseline counts: 45 

(Target) / 48 (Comparator)

Mid (12) Percent Change*: -47 .01 Percent Change*: -52

Parallel Mild/mod

È N=77 .01 0.01

Severity (leeds)

Count location: Face. 

Mid (12) Measure: 0 .01 Measure: 0 .01 0.05

E.02.03 Isotretinoin (0.05%) Isotretinoin (0.1%)

202 Closed comedones (count)

Count location: Face. Baseline counts: 23 

(Target) / 21 (Comparator)

Short (4) Percent Change*: -19 NS Percent Change*: -20

Parallel Mild/mod

N=82 NS NS*

Papules (count)

Count location: Face. Baseline counts: 23 

(Target) / 23 (Comparator)

Short (4) Percent Change*: -26 .01 Percent Change*: -32 .01 NS*

Closed comedones (count)

Count location: Face. Baseline counts: 23 

(Target) / 21 (Comparator)

Mid (12) Percent Change*: -47 .01 Percent Change*: -46 .01 NS*

Papules (count)

Count location: Face. Baseline counts: 23 

(Target) / 23 (Comparator)

Mid (12) Percent Change*: -34 .001 Percent Change*: -60 .01 NS*

E.02.04 Isotretinoin Tretinoin

90 Comedones (count)

Baseline counts: 40 (Target) / 33 

(Comparator)

Short (4) Percent Change*: -50 Percent Change*: -39

Parallel Mod

È N=30

Inflammatory (count)

Baseline counts: 13 (Target) / 13 

(Comparator)

Short (4) Percent Change*: -54 Percent Change*: -62

Comedones (count)

Baseline counts: 40 (Target) / 33 

(Comparator)

Mid (12) Percent Change*: -78 Percent Change*: -70

98 Comedones change (%) Mid (12) Percent change: -37 (49.) sig Percent change: -32 

Parallel (55.)

N=18 sig NS

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 7 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

90 Inflammatory (count)

Baseline counts: 13 (Target) / 13 

(Comparator)

Mid (12) Percent Change*: -77 Percent Change*: -77

Parallel Mod

È N=30

98 Inflammatory change (%) Mid (12) Percent change: -57 (25.) .01 Percent change: -46 

Parallel (29.)

N=18 .01 NS

Total lesions change (%) Mid (12) Percent change: -51 (27.) Percent change: -47 

(37.)

NS

E.03.01 Motretinide Vehicle

61 Comedones change (count)

Baseline counts: 9 (Target) / 9 (Comparator)

Short (4) Percent change*: -33 .05 Percent change*: -11

Parallel 

Í N=19 NS NS

Total lesions change (count)

Baseline counts: 12 (Target) / 16 

(Comparator)

Short (4) Percent change*: -42 .01 Percent change*: -13 NS NS

Comedones change (count)

Baseline counts: 9 (Target) / 9 (Comparator)

Mid (7) Percent change*: -67 .05 Percent change*: -11 NS NS

Total lesions change (count)

Baseline counts: 12 (Target) / 16 

(Comparator)

Mid (7) Percent change*: -75 .01 Percent change*: -23 NS NS

E.03.02 Motretinide (bid) Motretinide (qd)

253 Papules (count)

Baseline counts: 9 (Target) / 10 (Comparator)

Mid (8) Percent Change*: -56 .005 Percent Change*: -50

Parallel Mod/sev

È N=60 .01 NS

Pustules (count)

Baseline counts: 11 (Target) / 10 

(Comparator)

Mid (8) Percent Change*: -64 .001 Percent Change*: -70 .01 NS

E.03.03 Motretinide Tretinoin

59 Total lesions change (count/median)

Count location: Worst area/5cm diameter. 

Mid (8) Measure: -5 .01 Measure: -8

Parallel Mild

È N=37 .01 NS

E.03.03 Motretinide (bid) Tretinoin

253 Papules (count)

Baseline counts: 9 (Target) / 7 (Comparator)

Mid (8) Percent Change*: -56 .005 Percent Change*: -71

Parallel Mod/sev

È N=60 .001 NS

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 8 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

253 Pustules (count)

Baseline counts: 11 (Target) / 10 

(Comparator)

Mid (8) Percent Change*: -64 .001 Percent Change*: -50

Parallel Mod/sev

È N=60 .01 NS

E.03.03 Motretinide (qd) Tretinoin

253 Papules (count)

Baseline counts: 10 (Target) / 7 (Comparator)

Mid (8) Percent Change*: -50 .01 Percent Change*: -71

Parallel Mod/sev

È N=60 .001 NS

Pustules (count)

Baseline counts: 10 (Target) / 10 

(Comparator)

Mid (8) Percent Change*: -70 .01 Percent Change*: -50 .01 NS

E.04.01 Retinyl beta-glucuronide Vehicle

145 Total lesions (ratio to initial)

Count location: Side of face (spilt face trial). 

Short (4) Measure: 1 Measure: 1

Parallel Mild/mod

È N=29

Total lesions change (ratio to initial)

Count location: Side of face (split face trail). 

Mid (12) Measure: 1 Measure: 1

Overall change/physician (score)

Count location: Side of face (spilt face trial). 

Long (16 Measure: 3 Measure: 3

Inflammatory (count/median) Long (18 Measure: 23 .07 Measure: 27 NS

Inflammatory change (ratio to initial) Long (18 Measure: 1 Measure: 1

Non-inflammatory (count/median) Long (18 Measure: 10 .001 Measure: 11 .01

Non-inflammatory change (ratio to initial) Long (18 Measure: 0 Measure: 0

Total lesions (count/median) Long (18 Measure: 28 .002 Measure: 41 .06

Total lesions change (ratio to intitial) Long (18 Measure: 0 Measure: 1

E.04.02 Retinyl beta-glucuronide Tretinoin

146 Total lesions change (ratio to initial)

Count location: Side of face. 

Short (6) Measure: 1 Measure: 1

Parallel Mild/mod

È N=15

Total lesions change (ratio to initial) Mid (8) Measure: 1 Measure: 1

Inflammatory (count/median) Long (28 Measure: 3 Measure: 6

Inflammatory lesion (ration to initial) Long (28 Measure: 0 Measure: 0

Non-inflammatory (count/median) Long (28 Measure: 4 Measure: 6

Non-inflammatory change (ratio to initial) Long (28 Measure: 0 Measure: 0

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 9 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

146 Overall change/physician (score)

Count location: Side of face. 

Long (28 Measure: 4 .05 Measure: 4

Parallel Mild/mod

È N=15 .05

Total lesions (count/median) Long (28 Measure: 7 Measure: 10 NS

Total lesions change (ratio to initial) Long (28 Measure: 0 Measure: 0 0.06

E.05.01 Tretinoin Polyoprepolymer-2

219 Inflammatory change (%) Short (4) Percent change: -22 Percent change: -11

Parallel Mild/mod

È N=344

Non-inflammatory change (%) Short (4) Percent change: -25 (21.) Percent change: -5 NS

Total lesions change (%) Short (4) Percent change: -25 (21.) Percent change: -7

Inflammatory change (%) Mid (12) Percent change: -48 (92.) Percent change: -32 

(92.)

Non-inflammatory change (%) Mid (12) Percent change: -48 (12.) Percent change: -28 NS

Total lesions change (%) Mid (12) Percent change: -49 (12.) Percent change: -28 NS

E.05.01 Tretinoin (0.02%) Vehicle

58 Comedones severity (christiansen)

Count location: Worst area. 

Short (4) Measure: 118 Measure: 157

Parallel Sev

Í N=256 0.05

Nodes+cysts (score) Short (4) Measure: 10 Measure: 18 NS

Papules severity (christiansen) Short (4) Measure: 85 Measure: 108 NS

Pustules (score) Short (4) Measure: 64 Measure: 87 NS

Comedones (christiansen) Mid (8) Measure: 94 Measure: 131 0.01

Nodes+cysts (score) Mid (8) Measure: 9 Measure: 14 NS

Papules severity (christiansen) Mid (8) Measure: 76 Measure: 83 NS

Pustules (score) Mid (8) Measure: 42 Measure: 67 NS

E.05.01 Tretinoin (0.025%) Vehicle

198 Comedones (count)

Count location: 2.5 cm. Baseline counts: 29 

(Target) / 20 (Comparator)

Mid (12) Percent Change*: -62 Percent Change*: 25

Parallel 

È N=60

Papules (count)

Count location: 2.5 cm. Baseline counts: 10 

(Target) / 12 (Comparator)

Mid (12) Percent Change*: -80 Percent Change*: 317

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 10 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

198 Pustules (count)

Count location: 2.5 cm. Baseline counts: 2 

(Target) / 2 (Comparator)

Mid (12) Percent Change*: -87 Percent Change*: -65

Parallel 

È N=60

Severity/patient (vas) Mid (12) Measure: 20 Measure: 39

E.05.01 Tretinoin (0.05%) Vehicle

58 Comedones severity (christiansen)

Count location: Worst area. 

Short (4) Measure: 120 Measure: 157

Parallel Sev

Í N=256 0.01

Nodes+cysts (score) Short (4) Measure: 20 Measure: 18 NS

Papules severity (christiansen) Short (4) Measure: 92 Measure: 108 0.05

Pustules (score) Short (4) Measure: 71 Measure: 87 NS

Comedones (christiansen) Mid (8) Measure: 89 Measure: 131 0.01

Nodes+cysts (score) Mid (8) Measure: 15 Measure: 14 NS

Papules severity (christiansen) Mid (8) Measure: 61 Measure: 83 0.05

Pustules (score) Mid (8) Measure: 35 Measure: 67 NS

198 Comedones (count)

Count location: 2.5 cm. Baseline counts: 18 

(Target) / 20 (Comparator)

Mid (12) Percent Change*: -59 Percent Change*: 25

Parallel 

È N=60

Papules (count)

Count location: 2.5 cm. Baseline counts: 8 

(Target) / 12 (Comparator)

Mid (12) Percent Change*: -65 Percent Change*: 317

Pustules (count)

Count location: 2.5 cm. Baseline counts: 3 

(Target) / 2 (Comparator)

Mid (12) Percent Change*: -85 Percent Change*: -65

Severity/patient (vas) Mid (12) Measure: 18 Measure: 39

E.05.01 Tretinoin (ethanol) Vehicle

220 Inflammatory change (%)

Between P-value: vs vehicle.

Short (4) Percent change: -41 Percent change: -19

Parallel Mild/mod

N=215 0.05

Inflammatory change (%) Short (4) Percent change: -25 Percent change: -18 NS

Non-inflammatory change (%) Short (4) Percent change: -21 Percent change: -12 NS

Total lesions change (%) Short (4) Percent change: -23 Percent change: -15 NS

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 11 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

220 Non-inflammatory change (%)

Between P-value: vs vehicle.

Mid (12) Percent change: -40 Percent change: -25

Parallel Mild/mod

N=215 0.05

Total lesions change (%) Mid (12) Percent change: -40 Percent change: -24 0.05

E.05.01 Tretinoin (polyoprepolymer-2) Vehicle

220 Inflammatory change (%) Short (4) Percent change: -20 Percent change: -18

Parallel Mild/mod

N=215 NS

Non-inflammatory change (%)

Between P-value: vs tretinoin 

(polyoprepolymer 2).

Short (4) Percent change: -24 Percent change: -12 0.05

Total lesions change (%) Short (4) Percent change: -23 Percent change: -15 NS

Inflammatory change (%) Mid (12) Percent change: -39 Percent change: -19 0.05

Non-inflammatory change (%)

Between P-value: vs vehicle.

Mid (12) Percent change: -41 Percent change: -25 0.05

Total lesions change (%) Mid (12) Percent change: -41 Percent change: -24 0.05

E.05.01 Tretinoin + polyoprepolymer-2 Polyoprepolymer-2

219 Inflammatory change (%) Short (4) Percent change: -15 Percent change: -11

Parallel Mild/mod

È N=344 NS

Non-inflammatory change (%) Short (4) Percent change: -18 (21.) Percent change: -5 NS

Total lesions change (%) Short (4) Percent change: -18 (21.) Percent change: -7

Inflammatory change (%) Mid (12) Percent change: -46 Percent change: -32 

(92.)

NS

Non-inflammatory change (%) Mid (12) Percent change: -44 (12.) Percent change: -28 NS

Total lesions change (%) Mid (12) Percent change: -46 (12.) Percent change: -28 NS

E.05.02 Tretinoin Benzoyl peroxide

38 Comedones (count)

Count location: Entire face. Baseline counts: 

25 (Target) / 38 (Comparator)

Mid (12) Percent Change*: -88 .001 Percent Change*: -53

Parallel Mod

Í N=97 .001 0.01

Papules (count)

Count location: Entire face. Baseline counts: 

42 (Target) / 44 (Comparator)

Mid (12) Percent Change*: -59 .001 Percent Change*: -38 .001 0.01

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 12 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

38 Pustules (count)

Count location: Entire face. Baseline counts: 8 

(Target) / 10 (Comparator)

Mid (12) Percent Change*: -68 .001 Percent Change*: -63

Parallel Mod

Í N=97 .001 NS

E.05.02 Tretinoin Benzoyl peroxide (acetone)

221 Comedones (count)

Baseline counts: 27 (Target) / 23 

(Comparator)

Short (6) Percent Change*: -52 Percent Change*: -61

Parallel Mod

Í N=147 NS

Papules (count)

Count location: Withouski/simon. Baseline 

counts: 8 (Target) / 9 (Comparator)

Short (6) Percent Change*: -25 Percent Change*: -67 NS

Pustules (count)

Baseline counts: 4 (Target) / 4 (Comparator)

Short (6) Percent Change*: -44 Percent Change*: -83 NS

Comedones change (%) Mid (8) Percent change: -63 Percent change: -62 NS

Papules change (%) Mid (8) Percent change: -29 Percent change: -56 0.02

Pustules change (%) Mid (8) Percent change: -48 Percent change: -80 NS

E.05.02 Tretinoin Benzoyl peroxide (alcohol)

221 Comedones change (%) Mid (8) Percent change: -63 Percent change: -57

Parallel Mod

Í N=147 NS

Papules change (%) Mid (8) Percent change: -29 Percent change: -56 0.02

Pustules change (%) Mid (8) Percent change: -48 Percent change: -79 NS

E.05.04 Tretinoin Azelaic acid

188 Comedones (count/median) Mid (12) Measure: 18 Measure: 22

Parallel 

È N=289 NS

Comedones (count)

Baseline counts: 52 (Target) / 50 

(Comparator)

Long (20 Percent Change*: -81 Percent Change*: -78 NS

E.05.04 Tretinoin + vehicle Azelaic acid + glycolic acid

316 Dryness (severity) Short (4) Measure: 1 (1.6) Measure: 0 (1.6)

Parallel Mild

N=70 0.01

Erythema (severity) Short (4) Measure: 1 (1.4) Measure: 1 (1.4) NS

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 13 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

316 Inflammatory change (%) Short (4) Percent change: -23 Percent change: -46 

Parallel Mild (36.)

N=70

Non-inflammatory change (%) Short (4) Percent change: -32 Percent change: -18

Papules change (%) Short (4) Percent change: -23 Percent change: -45 

(43.)

Scaling (severity) Short (4) Measure: 0 (0.9) Measure: 0 (0.9) 0.007

Dryness (severity) Mid (12) Measure: 0 (0.9) Measure: 0 (0.9) NS

Erythema (severity) Mid (12) Measure: 1 (2.) Measure: 0 (2.) 0.026

Inflammatory change (%) Mid (12) Percent change: -28 

(120.)

Percent change: -55 

(120.)

NS

Non-inflammatory change (%) Mid (12) Percent change: -46 Percent change: -47 NS

Papules change (%) Mid (12) Percent change: -23 

(132.)

Percent change: -55 

(132.)

0.03

Scaling (severity) Mid (12) Measure: 0 (2.) Measure: 0 (2.) 0.001

E.05.07 Tretinoin (0.02%) Tretinoin (0.05%)

58 Comedones severity (christiansen)

Count location: Worst area. 

Short (4) Measure: 118 Measure: 120

Parallel Sev

Í N=256 0.05

Nodes+cysts (score) Short (4) Measure: 10 Measure: 20 NS

Papules severity (christiansen) Short (4) Measure: 85 Measure: 92 NS

Pustules (score) Short (4) Measure: 64 Measure: 71 NS

Comedones (christiansen) Mid (8) Measure: 94 Measure: 89 0.01

Nodes+cysts (score) Mid (8) Measure: 9 Measure: 15 NS

Papules severity (christiansen) Mid (8) Measure: 76 Measure: 61 NS

Pustules (score) Mid (8) Measure: 42 Measure: 35 NS

E.05.07 Tretinoin (0.025%) Tretinoin (0.05%)

198 Comedones (count)

Count location: 2.5 cm. Baseline counts: 29 

(Target) / 18 (Comparator)

Mid (12) Percent Change*: -62 Percent Change*: -59

Parallel 

È N=60

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 14 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

198 Papules (count)

Count location: 2.5 cm. Baseline counts: 10 

(Target) / 8 (Comparator)

Mid (12) Percent Change*: -80 Percent Change*: -65

Parallel 

È N=60

Pustules (count)

Count location: 2.5 cm. Baseline counts: 2 

(Target) / 3 (Comparator)

Mid (12) Percent Change*: -87 Percent Change*: -85

Severity/patient (vas) Mid (12) Measure: 20 Measure: 18

E.05.07 Tretinoin (polyoprepolymer-2) Tretinoin (ethanol)

220 Inflammatory change (%) Short (4) Percent change: -20 Percent change: -25

Parallel Mild/mod

N=215 NS

Non-inflammatory change (%)

Between P-value: vs tretinoin 

(polyoprepolymer 2).

Short (4) Percent change: -24 Percent change: -21 0.05

Total lesions change (%) Short (4) Percent change: -23 Percent change: -23 NS

Inflammatory change (%) Mid (12) Percent change: -39 Percent change: -41 0.05

Non-inflammatory change (%)

Between P-value: vs vehicle.

Mid (12) Percent change: -41 Percent change: -40 0.05

Total lesions change (%) Mid (12) Percent change: -41 Percent change: -40 0.05

E.05.07 Tretinoin + polyoprepolymer-2 Tretinoin

219 Inflammatory change (%) Short (4) Percent change: -15 Percent change: -22

Parallel Mild/mod

È N=344 NS

Non-inflammatory change (%) Short (4) Percent change: -18 (21.) Percent change: -25 

(21.)

NS

Total lesions change (%) Short (4) Percent change: -18 (21.) Percent change: -25 

(21.)

Inflammatory change (%) Mid (12) Percent change: -46 Percent change: -48 

(92.)

NS

Non-inflammatory change (%) Mid (12) Percent change: -44 (12.) Percent change: -48 

(12.)

NS

Total lesions change (%) Mid (12) Percent change: -46 (12.) Percent change: -49 

(12.)

NS

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 15 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

E.05.08 Tretinoin Methyl prednisolone + neomycin

13 Change (gprg) Short (4) Measure: 98 Measure: 88

Parallel split face 

Mild/mod/sev

N=68

Change (gprg) Short (4) Measure: 98 Measure: 88

Change (gprg) Mid (8) Measure: 126 Measure: 120

Change (gprg) Mid (8) Measure: 126 Measure: 120

Comedones (count) Mid (8) Raw count: 7 Raw count: 7

Comedones (count) Mid (8) Raw count: 7 Raw count: 7

Tretinoin Chloramphenical + 

hydrocortisone

E.05.09

37 Comedones change (count)

Count location: 5cm diameter. Baseline 

counts: 6 (Target) / 5 (Comparator)

Short (6) Percent change*: -99 Percent change*: -60

Parallel Mod

È N=56

Comedones change (count) Short (6) Percent change*: -99 Percent change*: -60

Cysts change (count)

Count location: 5 cm diameter. Baseline 

counts: 1 (Target) / 0 (Comparator)

Short (6) Percent change*: -67 Percent change*: -46 NS

Cysts change (count) Short (6) Percent change*: -67 Percent change*: -46 NS

Papules change (count)

Count location: 5 cm diameter. Baseline 

counts: 7 (Target) / 6 (Comparator)

Short (6) Percent change*: -42 Percent change*: -27

Papules change (count) Short (6) Percent change*: -42 Percent change*: -27

Pustules change (count)

Count location: 5 cm diameter. Baseline 

counts: 2 (Target) / 2 (Comparator)

Short (6) Percent change*: -62 Percent change*: -72

Pustules change (count) Short (6) Percent change*: -62 Percent change*: -72

Comedones change (count)

Count location: 5 cm diameter. Baseline 

counts: 6 (Target) / 5 (Comparator)

Mid (12) Percent change*: -76 .001 Percent change*: -81 .001 NS

Comedones change (count) Mid (12) Percent change*: -76 .001 Percent change*: -81 .001 NS

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 16 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

37 Cysts change (count)

Count location: 5 cm diameter. Baseline 

counts: 1 (Target) / 0 (Comparator)

Mid (12) Percent change*: -82 .001 Percent change*: -46

Parallel Mod

È N=56 NS

Cysts change (count) Mid (12) Percent change*: -82 .001 Percent change*: -46 NS

Overall change/patient (vas)

Count location: 5 cm diameter. 

Mid (12) Measure: -4 (2.4) .001 Measure: -3 (4.6) .001 NS*

Overall change/patient (vas) Mid (12) Measure: -4 (2.4) .001 Measure: -3 (4.6) .001 NS*

Papules change (count)

Count location: 5 cm diameter. Baseline 

counts: 7 (Target) / 6 (Comparator)

Mid (12) Percent change*: -47 Percent change*: -47 NS

Papules change (count) Mid (12) Percent change*: -47 Percent change*: -47 NS

Pustules change (count)

Count location: 5 cm diameter. Baseline 

counts: 2 (Target) / 2 (Comparator)

Mid (12) Percent change*: -83 .001 Percent change*: -78 .001 NS

Pustules change (count) Mid (12) Percent change*: -83 .001 Percent change*: -78 .001 NS

E.06.01 Vitamin A Vehicle

35 Comedones (group count)

Count location: Witkowski/simons. 

Mid (12) Percent Change*: -66 Percent Change*: -42

Parallel Mild/mod

È N=72

Comedones [female] (count)

Count location: Witkowski/simons. Baseline 

counts: 272 (Target) / 370 (Comparator)

Mid (12) Percent Change*: -64 Percent Change*: -35

Comedones [male] (count)

Count location: Witkowski/simons. Baseline 

counts: 1042 (Target) / 722 (Comparator)

Mid (12) Percent Change*: -67 Percent Change*: -46

Papules (group count)

Count location: Witkowski/simons. 

Mid (12) Percent Change*: -26 Percent Change*: -49

Papules [female] (group count) Mid (12) Percent Change*: -12 Percent Change*: -13

Papules [male] (group count) Mid (12) Percent Change*: -66 Percent Change*: -30

Pustules (total count) Mid (12) Percent Change*: -68 Percent Change*: -67

Pustules [female] (total count) Mid (12) Percent Change*: -94 Percent Change*: -92

Pustules [male] (total count) Mid (12) Percent Change*: -60 Percent Change*: -62

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 17 of 18

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

E.06.02 Vitamin A Sulfur + resorcinol

272 Total lesions change (%)

Count location: Left side. 

Long (14 Percent change: -62 Percent change: -16

Parallel 

N=189

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable E CONTINUOUS: Page 18 of 18

ÈÍ